<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00922311</url>
  </required_header>
  <id_info>
    <org_study_id>Novartis-ST-01</org_study_id>
    <nct_id>NCT00922311</nct_id>
  </id_info>
  <brief_title>Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade</brief_title>
  <official_title>Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen Mary Hospital, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objective: To investigate the potential anti-proteinuric efficacy of aliskiren, a novel
      direct renin inhibitor (DRI), in addition to angiotensin receptor blocker (ARB) in
      immunoglobulin A nephropathy (IgAN) patients at risk of developing progressive renal failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open-label pilot study in which IgAN patients with persistent proteinuria
      despite maximum dose of ARB treatment will be assigned to receive Aliskiren. There is the
      optional addition of other anti-hypertensive agents to achieve an optimal target blood
      pressure of &lt;130/80 mmHg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of urine protein excretion rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in serum creatinine, eGFR, serum potassium and albumin</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Titrate from 150 mg daily to 300 mg daily</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Rasilez</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 - 70 years of age

          -  Histologic diagnosis of IgA nephropathy

          -  Proteinuria &gt; 1 g/day or UPC &gt; 1 mg/mg or 113 mg/mmol at least twice

          -  Receiving treatment with the maximum dose of ARB for at least 3 months

          -  Patients who are willing to give written, informed consent

        Exclusion Criteria:

          -  eGFR &lt; 15 ml/min/1.73 sq.m

          -  UPC &gt;5000 mg/g or 570 mg/mmol, or &lt;500 mg/g or 57 mg/mmol

          -  Serum K+ &gt; 5.2 mmol/L

          -  Presence of bilateral renal artery stenosis

          -  Presence of diabetes mellitus

          -  Renal histology showing pathologies other than IgAN

          -  Known allergy to ARB or DRI

          -  Patients on ARB/ACEi combination within 12 weeks of randomization

          -  Concurrent treatment with corticosteroids, Nsaid, or immunosuppressant

          -  Patients with connective tissue disease or obstructive uropathy

          -  Patients with malignancy or conditions severely limiting life expectancy

          -  Female who are pregnant or intending to conceive

          -  Female of child-bearing age unwilling to practice contraception

          -  Patients who are unable to give informed consent

          -  Patients simultaneously participating in another study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sydney CW Tang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2009</study_first_submitted>
  <study_first_submitted_qc>June 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2009</study_first_posted>
  <last_update_submitted>July 2, 2015</last_update_submitted>
  <last_update_submitted_qc>July 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <name_title>Sydney CW Tang</name_title>
    <organization>The University of Hong Kong</organization>
  </responsible_party>
  <keyword>Proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

